Drug-Safety Index →

A pharmaceutical-risk monitoring agent polls ADW-122 weekly and, when the Drug-Safety Index — derived from openFDA serious adverse-event reporting, where 100 = safer and lower scores signal a surge in serious events — drops below 50 and shows a falling trend, it escalates an alert to the pharmacovigilance team and cross-references the IOM's top_drivers field to identify which drug categories are driving the surge. The methodology_version field ensures the alert captures the specific openFDA query window used, so pharmacovigilance analysts can reproduce the exact underlying data pull for regulatory submissions. Notably, the backtest shows this index has ranged from 0 to 100 (mean 66.6, stdev 33.5), meaning surges are real and historically material.

A Head of Pharmacovigilance at a specialty pharma company uses ADW-122 (currently at its observed maximum of 100.0, meaning the safest recent environment in the backtest) as a weekly dashboard anchor to track FDA adverse-event reporting trends without manually querying the openFDA API and normalizing report volumes. When the score falls sharply — as it has historically reached as low as 0.0 — the team has an immediate signal to pull product-specific adverse-event subsets from openFDA before a potential FDA inquiry, compressing their triage timeline from days to hours.